Cargando…

Turning the Tide against Antibiotic Resistance by Evaluating Novel, Halogenated Phenazine, Quinoline, and NH125 Compounds against Ureaplasma Species Clinical Isolates and Mycoplasma Type Strains

Escalating levels of antibiotic resistance in mycoplasmas, particularly macrolide resistance in Mycoplasma pneumoniae and M. genitalium, have narrowed our antibiotic arsenal. Further, mycoplasmas lack a cell wall and do not synthesize folic acid, rendering common antibiotics, such as beta-lactams, v...

Descripción completa

Detalles Bibliográficos
Autores principales: Valentine-King, Marissa A., Cisneros, Katherine, James, Margaret O., Huigens, Robert W., Brown, Mary B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6395908/
https://www.ncbi.nlm.nih.gov/pubmed/30642935
http://dx.doi.org/10.1128/AAC.02265-18
_version_ 1783399172245815296
author Valentine-King, Marissa A.
Cisneros, Katherine
James, Margaret O.
Huigens, Robert W.
Brown, Mary B.
author_facet Valentine-King, Marissa A.
Cisneros, Katherine
James, Margaret O.
Huigens, Robert W.
Brown, Mary B.
author_sort Valentine-King, Marissa A.
collection PubMed
description Escalating levels of antibiotic resistance in mycoplasmas, particularly macrolide resistance in Mycoplasma pneumoniae and M. genitalium, have narrowed our antibiotic arsenal. Further, mycoplasmas lack a cell wall and do not synthesize folic acid, rendering common antibiotics, such as beta-lactams, vancomycin, sulfonamides, and trimethoprim, of no value. To address this shortage, we screened nitroxoline, triclosan, and a library of 20 novel, halogenated phenazine, quinoline, and NH125 analogues against Ureaplasma species and M. hominis clinical isolates from urine. We tested a subset of these compounds (n = 9) against four mycoplasma type strains (M. pneumoniae, M. genitalium, M. hominis, and Ureaplasma urealyticum) using a validated broth microdilution or agar dilution method. Among 72 Ureaplasma species clinical isolates, nitroxoline proved most effective (MIC(90), 6.25 µM), followed by an N-arylated NH125 analogue (MIC(90), 12.5 µM). NH125 and its analogue had significantly higher MICs against U. urealyticum isolates than against U. parvum isolates, whereas nitroxoline did not. Nitroxoline exhibited bactericidal activity against U. parvum isolates but bacteriostatic activity against the majority of U. urealyticum isolates. Among the type strains, the compounds had the greatest activity against M. pneumoniae and M. genitalium, with 8 (80%) and 5 (71.4%) isolates demonstrating MICs of ≤12.5 µM, respectively. Triclosan also exhibited lower MICs against M. pneumoniae and M. genitalium. Overall, we identified a promising range of quinoline, halogenated phenazine, and NH125 compounds that showed effectiveness against M. pneumoniae and M. genitalium and found that nitroxoline, approved for use outside the United States for the treatment of urinary tract infections, and an N-arylated NH125 analogue demonstrated low MICs against Ureaplasma species isolates.
format Online
Article
Text
id pubmed-6395908
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-63959082019-03-12 Turning the Tide against Antibiotic Resistance by Evaluating Novel, Halogenated Phenazine, Quinoline, and NH125 Compounds against Ureaplasma Species Clinical Isolates and Mycoplasma Type Strains Valentine-King, Marissa A. Cisneros, Katherine James, Margaret O. Huigens, Robert W. Brown, Mary B. Antimicrob Agents Chemother Susceptibility Escalating levels of antibiotic resistance in mycoplasmas, particularly macrolide resistance in Mycoplasma pneumoniae and M. genitalium, have narrowed our antibiotic arsenal. Further, mycoplasmas lack a cell wall and do not synthesize folic acid, rendering common antibiotics, such as beta-lactams, vancomycin, sulfonamides, and trimethoprim, of no value. To address this shortage, we screened nitroxoline, triclosan, and a library of 20 novel, halogenated phenazine, quinoline, and NH125 analogues against Ureaplasma species and M. hominis clinical isolates from urine. We tested a subset of these compounds (n = 9) against four mycoplasma type strains (M. pneumoniae, M. genitalium, M. hominis, and Ureaplasma urealyticum) using a validated broth microdilution or agar dilution method. Among 72 Ureaplasma species clinical isolates, nitroxoline proved most effective (MIC(90), 6.25 µM), followed by an N-arylated NH125 analogue (MIC(90), 12.5 µM). NH125 and its analogue had significantly higher MICs against U. urealyticum isolates than against U. parvum isolates, whereas nitroxoline did not. Nitroxoline exhibited bactericidal activity against U. parvum isolates but bacteriostatic activity against the majority of U. urealyticum isolates. Among the type strains, the compounds had the greatest activity against M. pneumoniae and M. genitalium, with 8 (80%) and 5 (71.4%) isolates demonstrating MICs of ≤12.5 µM, respectively. Triclosan also exhibited lower MICs against M. pneumoniae and M. genitalium. Overall, we identified a promising range of quinoline, halogenated phenazine, and NH125 compounds that showed effectiveness against M. pneumoniae and M. genitalium and found that nitroxoline, approved for use outside the United States for the treatment of urinary tract infections, and an N-arylated NH125 analogue demonstrated low MICs against Ureaplasma species isolates. American Society for Microbiology 2019-02-26 /pmc/articles/PMC6395908/ /pubmed/30642935 http://dx.doi.org/10.1128/AAC.02265-18 Text en Copyright © 2019 Valentine-King et al. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Susceptibility
Valentine-King, Marissa A.
Cisneros, Katherine
James, Margaret O.
Huigens, Robert W.
Brown, Mary B.
Turning the Tide against Antibiotic Resistance by Evaluating Novel, Halogenated Phenazine, Quinoline, and NH125 Compounds against Ureaplasma Species Clinical Isolates and Mycoplasma Type Strains
title Turning the Tide against Antibiotic Resistance by Evaluating Novel, Halogenated Phenazine, Quinoline, and NH125 Compounds against Ureaplasma Species Clinical Isolates and Mycoplasma Type Strains
title_full Turning the Tide against Antibiotic Resistance by Evaluating Novel, Halogenated Phenazine, Quinoline, and NH125 Compounds against Ureaplasma Species Clinical Isolates and Mycoplasma Type Strains
title_fullStr Turning the Tide against Antibiotic Resistance by Evaluating Novel, Halogenated Phenazine, Quinoline, and NH125 Compounds against Ureaplasma Species Clinical Isolates and Mycoplasma Type Strains
title_full_unstemmed Turning the Tide against Antibiotic Resistance by Evaluating Novel, Halogenated Phenazine, Quinoline, and NH125 Compounds against Ureaplasma Species Clinical Isolates and Mycoplasma Type Strains
title_short Turning the Tide against Antibiotic Resistance by Evaluating Novel, Halogenated Phenazine, Quinoline, and NH125 Compounds against Ureaplasma Species Clinical Isolates and Mycoplasma Type Strains
title_sort turning the tide against antibiotic resistance by evaluating novel, halogenated phenazine, quinoline, and nh125 compounds against ureaplasma species clinical isolates and mycoplasma type strains
topic Susceptibility
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6395908/
https://www.ncbi.nlm.nih.gov/pubmed/30642935
http://dx.doi.org/10.1128/AAC.02265-18
work_keys_str_mv AT valentinekingmarissaa turningthetideagainstantibioticresistancebyevaluatingnovelhalogenatedphenazinequinolineandnh125compoundsagainstureaplasmaspeciesclinicalisolatesandmycoplasmatypestrains
AT cisneroskatherine turningthetideagainstantibioticresistancebyevaluatingnovelhalogenatedphenazinequinolineandnh125compoundsagainstureaplasmaspeciesclinicalisolatesandmycoplasmatypestrains
AT jamesmargareto turningthetideagainstantibioticresistancebyevaluatingnovelhalogenatedphenazinequinolineandnh125compoundsagainstureaplasmaspeciesclinicalisolatesandmycoplasmatypestrains
AT huigensrobertw turningthetideagainstantibioticresistancebyevaluatingnovelhalogenatedphenazinequinolineandnh125compoundsagainstureaplasmaspeciesclinicalisolatesandmycoplasmatypestrains
AT brownmaryb turningthetideagainstantibioticresistancebyevaluatingnovelhalogenatedphenazinequinolineandnh125compoundsagainstureaplasmaspeciesclinicalisolatesandmycoplasmatypestrains